Reperfusion options for acute pulmonary embolism

Reperfusion Treatment in Acute Pulmonary Embolism: A Multicenter Observational Study in the Nordic Countries

Observational Sahlgrenska University Hospital · NCT07003646

This project will try catheter-directed interventions or systemic thrombolysis in adults with acute pulmonary embolism to see which approach leads to better outcomes.

Quick facts

Study typeObservational
Enrollment220 (estimated)
Ages18 Years and up
SexAll
SponsorSahlgrenska University Hospital Academic / other
Locations13 sites (Aarhus and 12 other locations)
Trial IDNCT07003646 on ClinicalTrials.gov

What this trial studies

PE-NORDIC is a multicenter observational effort comparing outcomes for adults with acute pulmonary embolism who receive catheter-directed interventions (including mechanical thrombectomy devices such as FlowTriever® and catheter-directed thrombolysis) versus systemic thrombolysis. The study will collect real-world data from participating Nordic hospitals on survival, hemodynamic response, and bleeding complications. It is non-randomized and enrolls patients who are planned for or have already received these reperfusion methods, with a waiver of consent allowed if patients die before consent can be obtained. The project aims to describe how current reperfusion strategies perform in routine clinical practice across the region.

Who should consider this trial

Good fit: Adults (≥18 years) with confirmed acute pulmonary embolism who are planned for or have received catheter-directed intervention or systemic thrombolysis, including pregnant women, are eligible.

Not a fit: Patients undergoing surgical embolectomy as the primary reperfusion treatment or those already enrolled in an interventional catheter-directed trial are not expected to benefit from this observational comparison.

Why it matters

Potential benefit: If successful, it could help identify which reperfusion approach provides better survival and fewer serious bleeding complications for patients with high-risk or deteriorating pulmonary embolism.

How similar studies have performed: Industry-sponsored and single-arm trials have shown promising hemodynamic improvements with devices like FlowTriever, but randomized comparisons between catheter-directed interventions and standard care are still limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All adult patients (≥18 years), including pregnant women, with verified (CTPA, angiography or scintigraphy) acute pulmonary embolism who are planned for, or have received, treatment with catheter directed intervention or systemic thrombolysis
* Informed consent (for patients who do not survive before informed consent can be obtained, a waiver of consent applies)

Exclusion Criteria:

* Ongoing enrolment in interventional catheter directed intervention trial
* Surgical embolectomy as primary reperfusion treatment

Where this trial is running

Aarhus and 12 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Pulmonary EmbolismThrombolysisCatheter-directed interventionAspirational thrombectomyCatheter-directed tromboylsisHigh-risk PE
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.